Subtype
Malignant Peritoneal Neoplasm
CI-CAN-00001164Explore in graph →
124 active trials5 approved drugs
- NCIt
- C3538
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001164Explore in graph →
Clinical trials
502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (75)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01716715 | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02315430 | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 |
| clinicaltrials |
| NCT02487849 | HIPEC After Secondary Cytoreductive Operation in Patients With Platinum-sensitive Recurrence of Ovarian Carcinoma(HIPEC) | withdrawn | Phase 2 | 0 | Krankenhaus Barmherzige Schwestern LinzOTHER | 1 | Mar 4, 2020 | clinicaltrials |
| NCT00214058 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | completed | Phase 2 | 36 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT01248962 | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer | completed | Phase 2 | 146 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT00721162 | Study of Ramucirumab in Ovarian Cancer | completed | Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 2 | Sep 26, 2019 | clinicaltrials |
| NCT01305213 | Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 107 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2019 | clinicaltrials |
| NCT00093626 | Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01468909 | Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01540565 | Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01556841 | The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer(TRIOC) | completed | Phase 2 | 94 | University College, LondonOTHER | 1 | May 9, 2019 | clinicaltrials |
| NCT02349958 | Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy(HIPEC/IPHC) | unknown | Phase 2 | 200 | Bay Area Gynecology OncologyOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT02948101 | PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01381861 | Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma | completed | Phase 2 | 23 | Tracon Pharmaceuticals Inc.INDUSTRY | 1 | Mar 5, 2019 | clinicaltrials |
| NCT01083537 | Trial of Best Supportive Care and Either Cisplatin or Paclitaxel to Treat Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer and Inoperable Malignant Bowel Obstruction | terminated | Phase 1 / Phase 2 | 1 | University Health Network, TorontoOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT01010126 | Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer | completed | Phase 2 | 252 | National Cancer Institute (NCI)NIH | 2 | Jan 25, 2019 | clinicaltrials |
| NCT00939809 | A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Jan 15, 2019 | clinicaltrials |
| NCT01592383 | Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | completed | Phase 2 | 2 | University of ChicagoOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT01669798 | BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer | completed | Phase 2 | 32 | AA SecordOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00030706 | Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | — | Montefiore Medical CenterOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT00281632 | A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer | completed | Phase 2 | 35 | GlaxoSmithKlineINDUSTRY | 3 | Sep 17, 2018 | clinicaltrials |
| NCT00322881 | Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer | terminated | Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00856180 | Sequential Angiogenic Blockade for the Treatment of Recurrent Mullerian Malignancies | completed | Phase 2 | 20 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00768144 | Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 36 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 24, 2018 | clinicaltrials |
| NCT00301756 | Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential Tumors | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2018 | clinicaltrials |
| NCT00230542 | Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer | completed | Phase 2 | 44 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT01091428 | Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer | completed | Phase 2 | 191 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00408070 | Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 2 | 5 | UConn HealthOTHER | 1 | Mar 8, 2018 | clinicaltrials |
| NCT01188876 | Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00499252 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT01118052 | EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 22 | Gynecologic Oncology GroupNETWORK | 1 | Jan 11, 2018 | clinicaltrials |
| NCT00331422 | Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | terminated | Phase 2 | 7 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00652899 | Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer | terminated | Phase 2 | 14 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00903630 | Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 15 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01039207 | Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Sep 7, 2017 | clinicaltrials |
| NCT00354601 | Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00004221 | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer | terminated | Phase 2 | 12 | Gynecologic Oncology GroupNETWORK | 1 | Aug 9, 2017 | clinicaltrials |
| NCT01905163 | Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients(CILOVE) | completed | Phase 2 | 47 | Centre Jean PerrinOTHER | 1 | Jul 19, 2017 | clinicaltrials |
| NCT00045682 | CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 78 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00054119 | Karenitecin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer | completed | Phase 2 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Jul 13, 2017 | clinicaltrials |
| NCT00511992 | Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer | completed | Phase 2 | 20 | University of OklahomaOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00061308 | Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer | completed | Phase 2 | 75 | GlaxoSmithKlineINDUSTRY | 2 | Jun 9, 2017 | clinicaltrials |
| NCT01972516 | Tivozanib As Maintenance Therapy In GYN | terminated | Phase 2 | 4 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01175343 | RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 2 | May 24, 2017 | clinicaltrials |
| NCT01137071 | Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer | terminated | Phase 2 | 29 | Recepta BiopharmaINDUSTRY | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01669226 | First-line Intraperitoneal Cisplatin and Etoposide Chemotherapy for Ovarian Cancer(AICE) | completed | Phase 2 | 215 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Dec 19, 2016 | clinicaltrials |
| NCT01031381 | Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer(RADBEV) | completed | Phase 2 | 50 | University of PittsburghOTHER | 1 | Aug 30, 2016 | clinicaltrials |
| NCT02595021 | Total/Subtotal Colectomy in Ovarian Cancer | unknown | Phase 2 | 80 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jul 26, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Mar 10, 2020source: clinicaltrials